Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7346917 | 0.89 | SMN1; SMN2 (0.43) | ABCG2POLBSMN1; SMN2AGTR1L3MBTL1 | |
| SCHEMBL7346670 | 0.89 | AGTR1 (0.42) | ABCG2POLBSMN1; SMN2AGTR1L3MBTL1 | |
| SCHEMBL4638349 | 0.87 | AGTR1 (0.47) | ABCG2POLBSMN1; SMN2AGTR1L3MBTL1 | |
| SCHEMBL7772778 | 0.86 | ABCG2 (0.44) | ABCG2POLBSMN1; SMN2AGTR1L3MBTL1 | |
| SCHEMBL7352872 | 0.81 | ABCG2 (0.41) | ABCG2POLBSMN1; SMN2AGTR1L3MBTL1 | |
| SCHEMBL7346277 | 0.81 | MEN1 (0.44) | POLBSMN1; SMN2L3MBTL1HPGD | |
| SCHEMBL8783660 | 0.81 | SMN1; SMN2 (0.40) | ABCG2POLBSMN1; SMN2AGTR1L3MBTL1 | |
| SCHEMBL7344950 | 0.80 | ABCG2 (0.39) | ABCG2POLBSMN1; SMN2AGTR1L3MBTL1 | |
| SCHEMBL4814768 | 0.78 | AGTR1 (0.60) | AGTR1 | |
| SCHEMBL9136967 | 0.78 | POLB (0.46) | POLBSMN1; SMN2AGTR1L3MBTL1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0760815-A1 | PROCESSES FOR PREPARING 1-BUTYL-2-[2'-(2H-TETRAZOL-5-YL)-BIPHENYL-4-YLMETHYL]-1H-INDOLE-3-CARBOXYLIC ACID | SYNTEX (U.S.A.) INC. (US) | 1997-03-12 | — | — | EP | claimed |
| WO-1995032962-A1 | PROCESSES FOR PREPARING 1-BUTYL-2-[2'-(2H-TETRAZOL-5-YL)-BIPHENYL-4-YLMETHYL]-1H-INDOLE-3-CARBOXYLIC ACID | SYNTEX (U.S.A.) INC. (US) | 1995-12-07 | — | — | WO | claimed |
| US-5412102-A | Processes for preparing 1-butyl-2-[2'-(2H-tetrazol-5-yl) biphenyl-4-ylmethyl]-1H-indole-3-carboxylic acid | SYNTEX (U.S.A.) INC. (US) | 1995-05-02 | — | — | US | claimed |
| US-20070032533-A1 | Nitric oxide enhancing angiotensin II antagonist compounds, compositions and methods of use | NITROMED, INC. (US) | 2007-02-08 | — | — | US | disclosed |
| US-20070032533-A1 | Nitric oxide enhancing angiotensin II antagonist compounds, compositions and methods of use | NITROMED, INC. (US) | 2007-02-08 | — | — | US | disclosed |
| EP-0760815-A1 | PROCESSES FOR PREPARING 1-BUTYL-2-[2'-(2H-TETRAZOL-5-YL)-BIPHENYL-4-YLMETHYL]-1H-INDOLE-3-CARBOXYLIC ACID | SYNTEX (U.S.A.) INC. (US) | 1997-03-12 | — | — | EP | disclosed |
| WO-1995032962-A1 | PROCESSES FOR PREPARING 1-BUTYL-2-[2'-(2H-TETRAZOL-5-YL)-BIPHENYL-4-YLMETHYL]-1H-INDOLE-3-CARBOXYLIC ACID | SYNTEX (U.S.A.) INC. (US) | 1995-12-07 | — | — | WO | disclosed |
| US-5446121-A | Processes for preparing 1-butyl-2-[2'-(2H-tetrazol-5-yl) biphenyl-4-ylmethyl]-1H-indole-3-carboxylic acid | SYNTEX (U.S.A.) INC. (US) | 1995-08-29 | — | — | US | disclosed |
| US-5412102-A | Processes for preparing 1-butyl-2-[2'-(2H-tetrazol-5-yl) biphenyl-4-ylmethyl]-1H-indole-3-carboxylic acid | SYNTEX (U.S.A.) INC. (US) | 1995-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032533-A1 | Nitric oxide enhancing angiotensin II antagonist compounds, compositions and methods of use | AGTR2, AGTR1, REN | ABCG2 1983/4885POLB 2228/4885SMN1; SMN2 2701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.